CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech, Inc. has indicated that it expects to initiate a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, as a maintenance therapy for ovarian cancer patients in second or third complete remission. Genentech is developing GDC-0449 under a collaboration agreement with Curis and will be the sponsor of this study.
